DNM1L and diabetic kidney disease: We also provided in vivo evidence indicating that knock-in diabetic db/db mice mutating S600 in DRP1 to the non-phosphorylable alanine at position 600 (S600A) exhibited marked improvement in DKD progression and protected mitochondrial morphology and bioenergetics of podocytes.